Read + Share
Li R, Sexton WJ, Dhillon J, Berglund A, et al. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive
Urothelial Carcinoma In Situ of the Bladder. Clin Cancer Res 2023;29:3875-3881.
PMID: 37505486
|
 |
|
Li R, Sexton WJ, Dhillon J, Berglund A, et al. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive
Urothelial Carcinoma In Situ of the Bladder. Clin Cancer Res 2023;29:3875-3881.
PMID: 37505486
|
|
|
|